Table 2

Risk of herpes zoster: Andersen-Gill model with and without IPW

CharacteristicsAndersen-Gill model without IPWAndersen-Gill model with IPW
Adjusted HR (95% CI)P valueAdjusted HR (95% CI)P value
Female sex1.36 (1.10 to 1.68) 0.0051 1.13 (0.85 to 1.50)0.4122
Age per 10 years1.21 (1.13 to 1.31) <0.0001 1.25 (1.14 to 1.37) <0.0001
Glucocorticoids, 5–10 vs 0 mg/day1.42 (1.19 to 1.69) <0.0001 1.47 (1.17 to 1.85) 0.0008
Glucocorticoids, >10 vs 0 mg/day3.57 (2.36 to 5.39) <0.0001 4.42 (2.50 to 7.83) <0.0001
csDMARD treatment Reference Reference
Monoclonal anti-TNF antibodies1.73 (1.34 to 2.24) <0.0001 1.63 (1.17 to 2.28) 0.0042
Soluble TNF receptor fusion protein1.45 (1.09 to 1.94) 0.0121 1.28 (0.90 to 1.81)0.1687
T cell costimulation modulator1.25 (0.85 to 1.85)0.26081.45 (0.86 to 2.46)0.1652
B cell targeted therapy1.62 (1.21 to 2.18) 0.0013 1.57 (1.03 to 2.40) 0.0355
IL-6 inhibitors1.41 (1.06 to 1.89) 0.0200 1.44 (0.99 to 2.11)0.0578
JAK inhibitors3.23 (2.32 to 4.48) <0.0001 3.66 (2.38 to 5.63) <0.0001
  • P values <0.05 are shown in bold.

  • Weights were estimated using the variables age, sex, disease duration, DAS28, FFbH, previous treatment with bDMARDs/tsDMARDs and osteoporosis.

  • bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic DMARDs; DAS28, Disease Activity Score of 28 joints using the erythrocyte sedimentation rate; DMARDs, disease-modifying antirheumatic drugs; FFbH, Hannover Functional Status Questionnaire; IL-6, interleukin 6; IPW, inverse probability weights; JAK, Janus kinase; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.